Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community

The failure of torcetrapib: what have we learned?

(2008) T R Joy et al.   BRITISH JOURNAL OF PHARMACOLOGY

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

(2008) M J Forrest et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity

(2008) Menno Vergeer et al.   CIRCULATION

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – author's reply

(2008) Sheila A Doggrell   EXPERT OPINION ON PHARMACOTHERAPY

The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – correspondence

(2008) Charles L Shear   EXPERT OPINION ON PHARMACOTHERAPY

Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk

(2008) Alexander Thompson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Analysis of Recent Papers in Hypertension Jan Basile, MD, Senior Editor

(2008) Michael J. Bloch et al.   Journal of Clinical Hypertension

Common variation in theCETPgene and the implications for cardiovascular disease and its treatment: an updated analysis

(2008) Robin P F Dullaart et al.   PHARMACOGENOMICS